Anemia In Elderly Market

DelveInsight’s ‘Anemia in Elderly Market Insights, Epidemiology, and Market Forecast – 2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Anemia in Elderly in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.


The Anemia in Elderly market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Anemia in Elderly market Size from 2018 to 2030, segmented by seven major markets. The report also covers the current Anemia in Elderly treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the underlying market potential.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Anemia in Elderly: Disease Understanding and Treatment Algorithm

Anemia in Elderly Overview

According to the World Health Organization (WHO), anemia is defined as hemoglobin (Hb) levels <12.0 g/dL in women and <13.0 g/dL in men. It is a condition in which the number of red blood cells or the hemoglobin concentration within them is lower than normal. Anemia is frequently detected in the elderly and poses a major clinical burden. The prevalence of anemia increases dramatically with advancing age and will increase further due to population aging. Also, the condition is associated with increased morbidity and mortality and can lead to cardiovascular and neurological events


Anemia can be categorized into categories by underlying cause, i.e., Iron-deficiency Anemia, Renal/CKD anemia, chronic inflammation Anemia, Anemia due to cancers, and, in the absence of other identifiable causes, unexplained anemia.


Anemia is a very common complication in the immediate postoperative period, being present in up to 90% of patients after major surgery. According to the WHO, postoperative anemia could be classified as mild (hemoglobin 110–119 g.L-1 in women and 110–129 g.L-1 in men, respectively (110–119/129 g.L-1)), moderate (hemoglobin 80–109 g.L-1), or severe (hemoglobin < 80 g.L-1). Postoperative anemia may be multifactorial in origin, with pre-existing anemia, peri-operative blood loss, frequent blood sampling, and inadequate nutritional intake after surgery, all potentially having a role. Older persons are more likely to undergo major surgery and present with comorbidities, thus increasing the risk of postoperative anemia, and reducing its tolerability.


In patients undergoing major surgery with a high risk of developing moderate‐to‐severe postoperative anemia, hemoglobin and iron status should be checked on the day of surgery if it has not been already performed in the pre‐operative assessment. As ferritin levels will not be elevated by inflammation immediately after surgery, a postoperative ferritin concentration < 100 μg.L−1 within 24 h after surgery indicates insufficient iron stores to support erythropoiesis with the potential for significant falls in postoperative hemoglobin. Further markers of postoperative iron deficiency are transferrin saturation < 20% with ferritin concentrations 100–300 μg.L−1, or reticulocyte hemoglobin content < 28 pg. These values and parameters may signal the need for intervention in anemic patients.


Pharmacological optimization of postoperative hemoglobin and erythropoiesis should allow correction of iron deficiency and rapid recovery from postoperative anemia, leading to improved postoperative outcomes and improved quality of life. It may also reduce patient exposure to red cell transfusion and its related risk and complications, thus contributing further to improving surgical outcomes and patient safety.


The current market for anemia mainly consists of different formulations of intravenous iron, oral iron, erythropoietin stimulating agents, and other therapies such as B12 and folic acid supplementations. Some of the IV iron are as follows: Ferrlecit (sodium ferric gluconate complex in sucrose injection), Infed (iron dextran injection), and Venofer (iron sucrose injection), Feraheme (ferumoxytol injection) Monoferric (ferric derisomaltose), and Injectafer (ferric carboxymaltose injection). Among the oral iron therapies, Newmarket entrants are Auryxia (ferric citrate) (US, EU, JP) and Feraccru/Accrufer (EU). Currently, there are three HIF-PHIs in late-stage development in the US, including FibroGen’s roxadustat, Akebia’s vadadustat, and GlaxoSmithKline’s daprodustat. All three HIF-PHIs have already gained approval in Japan.


Anemia in Elderly Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Anemia in Elderly market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.


The DelveInsight Anemia in Elderly market report gives a thorough understanding of Anemia in Elderly by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Anemia in the Elderly in the US, Europe, and Japan.

Anemia in Elderly Epidemiology

The Anemia in Elderly epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.


Key Findings

The disease epidemiology covered in the report provides historical and forecasted Anemia in Elderly epidemiology segmented as the prevalent population of anemia in the Elderly (65+), type-specific cases of anemia in the elderly, severity-specific cases of anemia in the elderly, postoperative cases of anemia based on the type of surgery, and severity-specific cases of anemia in the surgical (orthopedic, cardiothoracic and gastrointestinal) population, IV treated postoperative patients. The report includes the prevalent scenario of Anemia in the Elderly in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Anemia in Elderly Epidemiology

The epidemiology segment also provides the Anemia in Elderly epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Prevalent population of Anemia in the Elderly in the 7MM countries was estimated to be 19,502,381 cases in 2020.

Anemia in Elderly Drug Chapters

The current market for anemia mainly consists of different formulations of intravenous iron, oral iron, erythropoietin stimulating agents, and other therapies such as B12 and folic acid supplementation.


Some of the IV iron are as follows: Ferrlecit (sodium ferric gluconate complex in sucrose injection), Infed (iron dextran injection), and Venofer (iron sucrose injection), Feraheme (ferumoxytol injection) Monoferric (ferric derisomaltose), and Injectafer (ferric carboxymaltose injection).


Among the oral iron therapies, Newmarket entrants are Auryxia (ferric citrate) (US, EU, JP) and Feraccru/Accrufer (EU). Auryxia is approved in Japan under the name Riona. Shield Therapeutics recently announced that it would launch Accrufer in the US on August 1, 2021.


In a head-to-head Phase III study against Ferinject/Injectafer (market-leading IV treatment), Accrufer demonstrated comparable effectiveness over 52 weeks and could be a more cost-effective alternative to IV iron.

Products detail in the report…


Anemia in Elderly Emerging Drugs


Roxadustat (FibroGen/AstraZeneca), oral medicine, is the first in a new class of HIF-PH inhibitors that promote erythropoiesis or red blood cells production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin. Roxadustat is currently approved in China, Japan, and Chile to treat anemia in CKD patients who are dialysis-dependent and non–dialysis-dependent. Recently, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis. However, European Medicines Agency’s gave Evrenzo (roxadustat) a positive opinion for the treatment of anemia symptoms in patients with chronic kidney disease.


Daprodustat /GSK1278863 (GlaxoSmithKline) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to treat patients with anemia due to CKD. Daprodustat is currently not approved as a treatment for anemia due to CKD or any other indication anywhere else in the world other than in Japan. Presently it is being evaluated in Phase III study for the treatment of Anemia.

Products detail in the report…

Anemia in Elderly Market Outlook

The Anemia in Elderly market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Anemia in Elderly market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.


This segment gives a thorough detail of Anemia in the Elderly market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.


According to DelveInsight, the Anemia in the Elderly market in the 7MM is expected to change in the study period 2018–2030.


Currently, there are three HIF-PHIs in late-stage development in the US, including FibroGen’s roxadustat, Akebia’s vadadustat, and GlaxoSmithKline’s daprodustat. All three HIF-PHIs have already gained approval in Japan, while roxadustat has also been approved in China. Recently, the Cardiovascular and Renal Drugs Advisory Committee of the FDA voted against approval of roxadustat for the treatment of anemia due to chronic kidney disease for patients not on dialysis and on dialysis. The FDA will consider the vote, independent opinions and recommendations from experts as it reviews the NDA. However, European Medicines Agency’s gave Evrenzo (roxadustat) a positive opinion for the treatment of anaemia symptoms in patients with chronic kidney disease


FibroGen, AstraZeneca, and Astellas co-develop the oral HIF-PH inhibitor, roxadustat, to treat anemia in CKD dialysis and CKD-ND patients. FibroGen and AstraZeneca are co-commercializing roxadustat in the US and China, while Astellas has licensed rights in Europe and Japan.


Key Findings

This section includes a glimpse of the Anemia in Elderly market in the 7MM. The market size of Anemia in the Elderly in the seven major markets was USD 3,680.7 million in 2020.


The United States: Market Outlook

This section provides Anemia in Elderly market size and market size by therapies of Anemia in Elderly in the 7MM market.


The United States accounts for the largest market size of Anemia in the Elderly compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Iron-containing oral preparations currently available in the market are innumerous, with various pharmaceutical forms, including pills, effervescent tablets, elixir, and so on. Newmarket entrants are Auryxia (ferric citrate) (US) and Feraccru/Accrufer (EU). Auryxia is approved in Japan under the name Riona. Auryxia (ferric citrate) is a member of the phosphate binder’s drug class and is commonly used for Hyperphosphatemia of Renal Failure and Iron Deficiency Anemia. Feraccru is an iron-containing compound. This helps correct reduced production of hemoglobin (the oxygen-carrying pigment in red blood cells), anemia (low levels of red blood cells), and any symptoms of the condition. Iron is an essential building block for hemoglobin, and the body can produce more hemoglobin and correct anemia once iron stores are replenished. Feraccru is all set to enter the US market by 2021.


For non-cancer patients with severe postoperative anemia and inflammation-induced blunted erythropoiesis or those declining blood transfusion, additional treatment with an erythropoiesis-stimulating agent (e.g., recombinant human erythropoietin [rHuEPO]) may be considered. Procrit (epoetin alfa) and Epogen (epoetin alfa) is an erythropoiesis-stimulating agent (ESA) in the United States, at a substantial discount. Mircera (methoxy polyethylene glycol-epoetin beta), a long-acting ESA, received FDA approval in November 2007 and is marketed by Roche in Europe. ESAs like Mircera and existing ESAs like ’Amgen’s Epogen and Aranesp are facing another competitor – ESA biosimilars.


EU-5 Countries: Market Outlook

The total Anemia in Elderly market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.


Japan Market Outlook

The total Anemia in Elderly market size and market size by therapies of Anemia in Elderly in Japan are also mentioned.

Anemia in Elderly Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Anemia in Elderly market uptake by drugs, patient uptake by therapies, and sales of each drug. 


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Anemia in Elderly Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses Anemia in Elderly key players involved in developing targeted therapeutics.


Major players include FibroGen, Akebia Therapeutics, GlaxoSmithKline, Bayer, and others, whose key products are expected to launch in the US market by 2030.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Anemia in Elderly emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Anemia in Elderly domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Anemia in Elderly market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Anemia in the Elderly market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Anemia in the Elderly, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Anemia in Elderly epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anemia in the Elderly is provided, along with the assessment of new therapies which will impact the current treatment landscape.
  • A detailed review of the Anemia in Elderly market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Anemia in the Elderly market

Report Highlights

  • In the coming years, the Anemia in the Elderly market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Anemia in Elderly R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Anemia in the Elderly. The launch of emerging therapies will significantly impact the Anemia in the Elderly market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Anemia in the Elderly.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Anemia in Elderly Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Anemia in Elderly Pipeline Analysis
  • Anemia in Elderly Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Anemia in Elderly Report Key Strengths

  • 10-years Forecast
  • 7MM Coverage
  • Anemia in Elderly Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Anemia in Elderly Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Anemia in Elderly Market share (%) distribution in 2018, and how would it look like in 2030?
  • What would be the Anemia in Elderly total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Anemia in Elderly market Size during the forecast period (2018–2030)?
  • At what CAGR, the Anemia in the Elderly market is expected to grow in the 7MM during the forecast period (2018–2030)?
  • What would be the Anemia in Elderly market outlook across the 7MM during the forecast period (2018–2030)?
  • What would be the Anemia in Elderly market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Anemia in the Elderly?
  • What is the historical Anemia in Elderly patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Anemia in the Elderly in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Anemia in the Elderly?
  • Out of all 7MM countries, which country would have the highest prevalence of Anemia in the Elderly during the forecast period (2018–2030)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2018–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Anemia in the Elderly?
  • What are the current treatment guidelines for treating Anemia in the Elderly in the US, Europe, and Japan?
  • What is the Anemia in Elderly marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Anemia in Elderly?
  • How many therapies are developed by each company for the treatment of Anemia in the Elderly?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Anemia in the Elderly?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anemia in Elderly therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Anemia in the Elderly and their status?
  • What are the key designations that have been granted for the emerging therapies for Anemia in the Elderly?
  • What are the global historical and forecasted markets for Anemia in the Elderly?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Anemia in the Elderly market
  • To understand the future market competition in the Anemia in Elderly market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Anemia in the Elderly in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Anemia in Elderly market.
  • To understand the future market competition in the Anemia in Elderly market.

1. Key Insights

2. Report Introduction

3. Anemia Market Overview at a Glance

3.1. Market Share (%) Distribution of Anemia in Elderly in 2018

3.2. Market Share (%) Distribution of Anemia in Elderly in 2030

4. Executive Summary of Anemia

5. Disease Background and Overview

5.1. Introduction

5.2. Etiology

5.3. Clinical Manifestations

5.4. Pathophysiology

5.5. Classification of anemia

5.6. Diagnosis

5.7. Treatment

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Population of Anemia in Elderly (65+)

6.3. Epidemiology of Anemia in Elderly (65+)

6.4. The United States

6.4.1. Prevalent Cases of Anemia in Elderly (65+) in the United States

6.4.2. Type-specific Cases of Anemia in Elderly in the United States

6.4.3. Severity-specific Prevalence of Anemia in Elderly in the United States

6.4.4. Cases of Anemia based on the type of surgery in the United States

6.4.5. Severity-specific cases of Anemia in orthopedic population in the United States

6.4.6. Severity-specific cases of Anemia in cardiothoracic population in the United States

6.4.7. Severity-specific cases of Anemia in gastrointestinal surgeries in the United States

6.4.8. IV Treated Postoperative Patients in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Prevalent Cases of Anemia in Elderly (65+) in Germany

6.5.1.2. Type-specific Cases of Anemia in Germany

6.5.1.3. Severity-specific Prevalence of Anemia in Germany

6.5.1.4. Cases of Anemia based on the type of surgery in Germany

6.5.1.5. Severity-specific cases of Anemia in orthopedic population in Germany

6.5.1.6. Severity-specific cases of Anemia in cardiothoracic population in Germany

6.5.1.7. Severity-specific cases of Anemia in gastrointestinal surgeries in Germany

6.5.1.8. IV Treated Postoperative Patients in Germany

6.5.2. France

6.5.2.1. Prevalent Cases of Anemia in Elderly (65+) in France

6.5.2.2. Type-specific Cases of Anemia in France

6.5.2.3. Severity-specific Prevalence of Anemia in France

6.5.2.4. Cases of Anemia based on the type of surgery in France

6.5.2.5. Severity-specific cases of Anemia in orthopedic population in France

6.5.2.6. Severity-specific cases of Anemia in cardiothoracic population in France

6.5.2.7. Severity-specific cases of Anemia in gastrointestinal surgeries in France

6.5.2.8. IV Treated Postoperative Patients in France

6.5.3. Italy

6.5.3.1. Prevalent Cases of Anemia in Elderly (65+) in Italy

6.5.3.2. Type-specific Cases of Anemia in Italy

6.5.3.3. Severity-specific Prevalence of Anemia in Italy

6.5.3.4. Cases of Anemia based on the type of surgery in Italy

6.5.3.5. Severity-specific cases of Anemia in orthopedic population in Italy

6.5.3.6. Severity-specific cases of Anemia in cardiothoracic population in Italy

6.5.3.7. Severity-specific cases of Anemia in gastrointestinal surgeries in Italy

6.5.3.8. IV Treated Postoperative Patients in Italy

6.5.4. Spain

6.5.4.1. Prevalent Cases of Anemia in Elderly (65+) in Spain

6.5.4.2. Type-specific Cases of Anemia in Spain

6.5.4.3. Severity-specific Prevalence of Anemia in Spain

6.5.4.4. Cases of Anemia based on the type of surgery in Spain

6.5.4.5. Severity-specific cases of Anemia in orthopedic population in Spain

6.5.4.6. Severity-specific cases of Anemia in cardiothoracic population in Spain

6.5.4.7. Severity-specific cases of Anemia in gastrointestinal surgeries in Spain

6.5.4.8. IV Treated Postoperative Patients in Spain

6.5.5. The United Kingdom

6.5.5.1. Prevalent Cases of Anemia in Elderly (65+) in the UK

6.5.5.2. Type-specific Cases of Anemia in the UK

6.5.5.3. Severity-specific Prevalence of Anemia in the UK

6.5.5.4. Cases of Anemia based on the type of surgery in the UK

6.5.5.5. Severity-specific cases of Anemia in orthopedic population in the UK

6.5.5.6. Severity-specific cases of Anemia in cardiothoracic population in the UK

6.5.5.7. Severity-specific cases of Anemia in gastrointestinal surgeries in the UK

6.5.5.8. IV Treated Postoperative Patients in the UK

6.6. Japan

6.6.1. Prevalent Cases of Anemia in Elderly (65+) in Japan

6.6.2. Type-specific Cases of Anemia in Japan

6.6.3. Severity-specific Prevalence of Anemia in Japan

6.6.4. Cases of Anemia based on the type of surgery in Japan

6.6.5. Severity-specific cases of Anemia in orthopedic population in Japan

6.6.6. Severity-specific cases of Anemia in cardiothoracic population in Japan

6.6.7. Severity-specific cases of Anemia in gastrointestinal surgeries in Japan

6.6.8. IV Treated Postoperative Patients in Japan

7. Organizations contributing toward the fight against Anemia

8. Patient Journey

9. Case Reports

10. Marketed Products

10.1. Key cross Competition

10.2. Feraheme (Ferumoxytol Injection): AMAG Pharmaceuticals

10.2.1. Product Description

10.2.2. Mechanism of action

10.2.3. Regulatory Milestones

10.2.4. Safety and Efficacy of FERAHEME

10.2.5. Side Effects of FERAHEME

10.2.6. Product Profile

10.3. Venofer (iron sucrose): Vifor Pharma Inc.

10.3.1. Product Description

10.3.2. Mechanism of action

10.3.3. Regulatory Milestones

10.3.4. Safety and Efficacy of Venofer

10.3.5. Side effects of Venofer

10.3.6. Product Profile

10.4. Triferic (Ferric Pyrophosphate Citrate): Rockwell Medical.

10.4.1. Product Description

10.4.2. Mechanism of action

10.4.3. Regulatory Milestones

10.4.4. Safety and Efficacy of Triferic

10.4.5. Side Effects of Triferic

10.4.6. Product Profile

10.5. Auryxia (Ferric Citrate): Keryx Biopharmaceuticals Inc.

10.5.1. Product Description

10.5.2. Mechanism of action

10.5.3. Regulatory Milestones

10.5.4. Safety and Efficacy of AURYXIA

10.5.5. Side Effects of AURYXIA

10.5.6. Product Profile

10.6. FERRLECIT (Sodium Ferric Gluconate Complex in Sucrose Injection): Sanofi-Aventis U.S. LLC.

10.6.1. Product Description

10.6.2. Mechanism of Action

10.6.3. Regulatory Milestones

10.6.4. Safety and Efficacy of FERRLECIT

10.6.5. Side Effects of FERRLECIT

10.6.6. Product Profile

10.7. Accrufer/Feraccru (Ferric Maltol): Shield Therapeutics plc.

10.7.1. Product Description

10.7.2. Mechanism of action

10.7.3. Regulatory Milestones

10.7.4. Safety and Efficacy of ACCRUFER

10.7.5. Side Effects of ACCRUFER

10.7.6. Product Profile

10.8. Monoferric (Ferric Derisomaltose): Pharmacosmos A/S

10.8.1. Product Description

10.8.2. Mechanism of action

10.8.3. Regulatory milestones

10.8.4. Safety and Efficacy

10.8.5. Side Effects of Monoferric

10.8.6. Product profile

10.9. Injectafer (Ferric Carboxymaltose Injection): American Regent/Vifor

10.9.1. Product Description

10.9.2. Mechanism of Action

10.9.3. Regulatory Milestones

10.9.4. Safety and efficacy of Injectafer

10.9.5. Product Profile

10.10. Procrit (Epoetin Alfa): Amgen Inc.

10.10.1. Product Description

10.10.2. Mechanism of action

10.10.3. Regulatory Milestones

10.10.4. Safety and Efficacy of PROCRIT

10.10.5. Side effects of PROCRIT

10.10.6. Product Profile

10.11. ENAROY (Enarodustat): Japan Tobacco

10.11.1. Drug Description

10.11.2. Other development activities

10.11.3. Clinical Development

10.11.4. Clinical trial information

10.11.5. Safety and Efficacy

10.11.6. Product Profile

11. Emerging Therapies

11.1. Key Cross Competition

11.2. Roxadustat: FibroGen/AstraZeneca

11.2.1. Drug Description

11.2.2. Other Development Activities

11.2.3. Clinical Development

11.2.4. Clinical Trial Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Daprodustat: GlaxoSmithKline

11.3.1. Drug Description

11.3.2. Other Development Activities

11.3.3. Clinical Development

11.3.4. Clinical Trial Information

11.3.5. Safety and Efficacy

11.3.6. Product Profile

11.4. Vadadustat: Akebia Therapeutics

11.4.1. Drug Description

11.4.2. Other Development Activities

11.4.3. Clinical Development

11.4.4. Clinical Trial Information

11.4.5. Safety and Efficacy

11.4.6. Product Profile

12. Other Assets

12.1. Key cross Other Assets

12.2. BGE-117: BioAge Labs Inc.

12.2.1. Drug Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Clinical Trial Information

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. IDAX (IHAT-02): Nemysis

12.3.1. Drug Description

12.3.2. Product Profile

12.4. MPB-1514: MegaPro Biomedical

12.4.1. Drug Description

12.4.2. Clinical Development

12.4.3. Clinical Trial Information

12.4.4. Product Profile

12.5. Molidustat (BAY85-3934): Bayer

12.5.1. Drug Description

12.5.2. Clinical Development

12.5.3. Clinical trial information

12.5.4. Safety and Efficacy

12.5.5. Product Profile

13. Anemia in Elderly: Seven Major Market Analysis

13.1. Key Findings

13.2. Market Size of Anemia in 7MM

13.3. Market Outlook

13.4. United States Market Size

13.4.1. Total Market Size of Anemia in United States

13.4.2. Market Size of Anemia by Therapies in United States

13.5. EU-5 Market

13.5.1. Germany

13.5.1.1. Total Market Size of Anemia in Germany

13.5.1.2. Market Size of Anemia by Therapies in Germany

13.5.2. France

13.5.2.1. Total Market Size of Anemia in France

13.5.2.2. Market Size of Anemia by Therapies in France

13.5.3. Italy

13.5.3.1. Total Market Size of Anemia in Italy

13.5.3.2. Market Size of Anemia by Therapies in Italy

13.5.4. Spain

13.5.4.1. Total Market Size of Anemia in Spain

13.5.4.2. Market Size of Anemia by Therapies in Spain

13.5.5. United Kingdom

13.5.5.1. Total Market Size of Anemia in United Kingdom

13.5.5.2. Market Size of Anemia by Therapies in the United Kingdom

13.6. Japan Market Size

13.6.1.1. Total Market Size of Anemia in Japan

13.6.1.2. Market Size of Anemia by Therapies in Japan

14. KOL Views

15. Unmet Needs

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Table

Table 1: Summary of Anemia, Epidemiology, and Key Events (2018–2030)

Table 2: Causes with the associated condition of IDA

Table 3: Prevalence Population of Anemia in elderly (65+) in 7MM (2018–2030)

Table 4: Prevalent Cases of Anemia in Elderly (65+) in the United States (2018–2030)

Table 5: Type-specific Cases of Anemia in Elderly in the United States (2018–2030)

Table 6: Severity-specific Prevalence of Anemia in Elderly in the United States (2018–2030)

Table 7: Cases of Anemia based on the type of surgery in the United States (2018–2030)

Table 8: Severity-specific cases of Anemia in orthopedic population in the United States (2018–2030)

Table 9: Severity-specific cases of Anemia in cardiothoracic population in the United States (2018–2030)

Table 10: Severity-specific cases of Anemia in gastrointestinal surgeries in the United States (2018–2030)

Table 11: IV Treated Postoperative Patients in the United States (2018–2030)

Table 12: Prevalent Cases of Anemia in Elderly (65+) in Germany in 000’s (2018–2030)

Table 13: Type-specific Cases of Anemia in Elderly in Germany (2018–2030)

Table 14: Severity-specific Prevalence of Anemia in Elderly in Germany (2018–2030)

Table 15: Cases of Anemia based on the type of surgery in Germany (2018–2030)

Table 16: Severity-specific cases of Anemia in orthopedic population in Germany (2018–2030)

Table 17: Severity-specific cases of Anemia in cardiothoracic population in Germany (2018–2030)

Table 18: Severity-specific cases of Anemia in gastrointestinal surgeries in Germany (2018–2030)

Table 19: IV Treated Postoperative Patients in Germany (2018–2030)

Table 20: Prevalent Cases of Anemia in Elderly (65+) in France (2018–2030)

Table 21: Type-specific Cases of Anemia in Elderly in France (2018–2030)

Table 22: Severity-specific Prevalence of Anemia in Elderly in France (2018–2030)

Table 23: Cases of Anemia based on the type of surgery in France (2018–2030)

Table 24: Severity-specific cases of Anemia in orthopedic population in France (2018–2030)

Table 25: Severity-specific cases of Anemia in cardiothoracic population in France (2018–2030)

Table 26: Severity-specific cases of Anemia in gastrointestinal surgeries in France (2018–2030)

Table 27: IV Treated Postoperative Patients in France (2018–2030)

Table 28: Prevalent Cases of Anemia in Elderly (65+) in Italy (2018–2030)

Table 29: Type-specific Cases of Anemia in Elderly in Italy (2018–2030)

Table 30: Severity-specific Prevalence of Anemia in Elderly in Italy (2018–2030)

Table 31: Cases of Anemia based on the type of surgery in Italy (2018–2030)

Table 32: Severity-specific cases of Anemia in orthopedic population in Italy (2018–2030)

Table 33: Severity-specific cases of Anemia in cardiothoracic population in Italy (2018–2030)

Table 34: Severity-specific cases of Anemia in gastrointestinal surgeries in Italy (2018–2030)

Table 35: IV Treated Postoperative Patients in Italy (2018–2030)

Table 36: Prevalent Cases of Anemia in Elderly (65+) in Spain (2018–2030)

Table 37: Type-specific Cases of Anemia in Elderly in Spain (2018–2030)

Table 38: Severity-specific Prevalence of Anemia in Elderly in Spain (2018–2030)

Table 39: Cases of Anemia based on the type of surgery in Spain (2018–2030)

Table 40: Severity-specific cases of Anemia in orthopedic population in Spain (2018–2030)

Table 41: Severity-specific cases of Anemia in cardiothoracic population in Spain (2018–2030)

Table 42: Severity-specific cases of Anemia in gastrointestinal surgeries in Spain (2018–2030)

Table 43: IV Treated Postoperative Patients in Spain (2018–2030)

Table 44: Prevalent Cases of Anemia in Elderly (65+) in the United Kingdom in 000’s (2018–2030)

Table 45: Type-specific Cases of Anemia in Elderly in the United Kingdom (2018–2030)

Table 46: Severity-specific Prevalence of Anemia in Elderly the United Kingdom (2018–2030)

Table 47: Cases of Anemia based on the type of surgery in the United Kingdom (2018–2030)

Table 48: Severity-specific cases of Anemia in orthopedic population the United Kingdom (2018–2030)

Table 49: Severity-specific cases of Anemia in cardiothoracic population in the United Kingdom (2018–2030)

Table 50: Severity-specific cases of Anemia in gastrointestinal surgeries in the United Kingdom (2018–2030)

Table 51: IV Treated Postoperative Patients in the United Kingdom (2018–2030)

Table 52: Prevalent Cases of Anemia in Elderly (65+) in Japan in 000’s (2018–2030)

Table 53: Type-specific Cases of Anemia in Elderly in Japan in 000’s (2018–2030)

Table 54: Severity-specific Prevalence of Anemia in Elderly in Japan (2018–2030)

Table 55: Cases of Anemia based on the type of surgery in Japan (2018–2030)

Table 56: Severity-specific cases of Anemia in orthopedic population in Japan (2018–2030)

Table 57: Severity-specific cases of Anemia in cardiothoracic population in Japan (2018–2030)

Table 58: Severity-specific cases of Anemia in gastrointestinal surgeries in Japan (2018–2030)

Table 59: IV Treated Postoperative Patients in Japan (2018–2030)

Table 60: Organizations contributing towards the fight against Anemia

Table 61: Key cross of the Marketed drugs

Table 62: Key cross of the Marketed drugs

Table 63: ENAROY, Clinical Trial Description, 2021

Table 64: Roxadustat, Clinical Trial Description, 2021

Table 65: Daprodustat, Clinical Trial Description, 2021

Table 66: Vadadustat, Clinical Trial Description, 2021

Table 67: BGE-117, Clinical Trial Description, 2021

Table 68: MPB-1514, Clinical Trial Description, 2021

Table 69: Molidustat (BAY85-3934), Clinical Trial Description, 2021

Table 70: Seven Major Market Size of Anemia in USD Million (2018–2030)

Table 71: The US Market Size of Anemia in USD Million (2018–2030)

Table 72: The US Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 73: The Germany Market Size of Anemia in USD Million (2018–2030)

Table 74: The Germany Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 75: The France Market Size of Anemia in USD Million (2018–2030)

Table 76: The France Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 77: The Italy Market Size of Anemia in USD Million (2018–2030)

Table 78: The Italy Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 79: The Spain Market Size of Anemia in USD Million (2018–2030)

Table 80: The Spain Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 81: The United Kingdom Market Size of Anemia in USD Million (2018–2030)

Table 82: The United Kingdom Market Size of Anemia by Therapies in USD Million (2018–2030)

Table 83: Japan Market Size of Anemia in USD Million (2018–2030)

Table 84: Japan Market Size of Anemia by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Causes of Iron deficiency anemia

Figure 2: Mechanisms of hepcidin inhibition in iron deficiency anemia

Figure 3: Types of anemia

Figure 4: Diagnostic tests for IDA

Figure 5: Algorithm for the diagnosis of IDA

Figure 6: Iron treatments for IDA

Figure 7: Oral vs. Intravenous iron

Figure 8: Treatment algorithm for IDA

Figure 9: Postoperative anemia management

Figure 10: Total Prevalent Population of Anemia in elderly (65+) in 7MM (2018–2030)

Figure 11: Prevalent Cases of Anemia in Elderly (65+) in the United States (2018–2030)

Figure 12: Type-specific Cases of Anemia in Elderly in the United States (2018–2030)

Figure 13: Severity-specific Prevalence of Anemia in Elderly in the United States (2018–2030)

Figure 14: Cases of Anemia based on the type of surgery in the United States (2018–2030)

Figure 15: Severity-specific cases of Anemia in orthopedic population in the United States (2018–2030)

Figure 16: Severity-specific cases of Anemia in cardiothoracic population in the United States (2018–2030)

Figure 17: Severity-specific cases of Anemia in gastrointestinal surgeries in the United States (2018–2030)

Figure 18: IV Treated Postoperative Patients in the United States (2018–2030)

Figure 19: Prevalent Cases of Anemia in Elderly (65+) in Germany (2018–2030)

Figure 20: Type-specific Cases of Anemia in Elderly in Germany (2018–2030)

Figure 21: Severity-specific Prevalence of Anemia in Elderly in Germany (2018–2030)

Figure 22: Cases of Anemia based on the type of surgery in Germany (2018–2030)

Figure 23: Severity-specific cases of Anemia in orthopedic population in Germany (2018–2030)

Figure 24: Severity-specific cases of Anemia in cardiothoracic population in Germany (2018–2030)

Figure 25: Severity-specific cases of Anemia in gastrointestinal surgeries in Germany (2018–2030)

Figure 26: IV Treated Postoperative Patients in Germany (2018–2030)

Figure 27: Prevalent Cases of Anemia in Elderly (65+) in France (2018–2030)

Figure 28: Type-specific Cases of Anemia in Elderly in France (2018–2030)

Figure 29: Severity-specific Prevalence of Anemia in Elderly in France (2018–2030)

Figure 30: Cases of Anemia based on the type of surgery in France (2018–2030)

Figure 31: Severity-specific cases of Anemia in orthopedic population in France (2018–2030)

Figure 32: Severity-specific cases of Anemia in cardiothoracic population in France (2018–2030)

Figure 33: Severity-specific cases of Anemia in gastrointestinal surgeries in France (2018–2030)

Figure 34: IV Treated Postoperative Patients in France (2018–2030)

Figure 35: Prevalent Cases of Anemia in Elderly (65+) in Italy (2018–2030)

Figure 36: Type-specific Cases of Anemia in Elderly in Italy (2018–2030)

Figure 37: Severity-specific Prevalence of Anemia in Elderly in Italy (2018–2030)

Figure 38: Cases of Anemia based on the type of surgery in Italy (2018–2030)

Figure 39: Severity-specific cases of Anemia in orthopedic population in Italy (2018–2030)

Figure 40: Severity-specific cases of Anemia in cardiothoracic population in Italy (2018–2030)

Figure 41: Severity-specific cases of Anemia in gastrointestinal surgeries in Italy (2018–2030)

Figure 42: IV Treated Postoperative Patients in Italy (2018–2030)

Figure 43: Prevalent Cases of Anemia in Elderly (65+) in Spain (2018–2030)

Figure 44: Type-specific Cases of Anemia in Elderly in Spain (2018–2030)

Figure 45: Severity-specific Prevalence of Anemia in Elderly in Spain (2018–2030)

Figure 46: Cases of Anemia based on the type of surgery in Spain (2018–2030)

Figure 47: Severity-specific cases of Anemia in orthopedic population in Spain (2018–2030)

Figure 48: Severity-specific cases of Anemia in cardiothoracic population in Spain (2018–2030)

Figure 49: Severity-specific cases of Anemia in gastrointestinal surgeries in Spain (2018–2030)

Figure 50: IV Treated Postoperative Patients in Spain (2018–2030)

Figure 51: Prevalent Cases of Anemia in Elderly (65+) in the United Kingdom 2018–2030)

Figure 52: Type-specific Cases of Anemia in Elderly in the United Kingdom (2018–2030)

Figure 53: Severity-specific Prevalence of Anemia in Elderly in the United Kingdom (2018–2030)

Figure 54: Cases of Anemia based on the type of surgery in the United Kingdom (2018–2030)

Figure 55: Severity-specific cases of Anemia in orthopedic population the United Kingdom (2018–2030)

Figure 56: Severity-specific cases of Anemia in cardiothoracic population in the United Kingdom (2018–2030)

Figure 57: Severity-specific cases of Anemia in gastrointestinal surgeries in the United Kingdom (2018–2030)

Figure 58: IV Treated Postoperative Patients in the United Kingdom (2018–2030)

Figure 59: Prevalent Cases of Anemia in Elderly (65+) in Japan (2018–2030)

Figure 60: Type-specific Cases of Anemia in Elderly in Japan (2018–2030)

Figure 61: Severity-specific Prevalence of Anemia in Elderly in Japan (2018–2030)

Figure 62: Cases of Anemia based on the type of surgery in Japan (2018–2030)

Figure 63: Severity-specific cases of Anemia in orthopedic population in Japan (2018–2030)

Figure 64: Severity-specific cases of Anemia in cardiothoracic population in Japan (2018–2030)

Figure 65: Severity-specific cases of Anemia in gastrointestinal surgeries in Japan (2018–2030)

Figure 66: IV Treated Postoperative Patients in Japan (2018–2030)

Figure 67: Seven Major Market Size of Anemia in USD Million (2018–2030)

Figure 68: The US Market Size of Anemia in USD Million (2018–2030)

Figure 69: The US Market Size of Anemia by Therapies (2018–2030)

Figure 70: The Germany Market Size of Anemia in USD Million (2018–2030)

Figure 71: The Germany Market Size of Anemia by Therapies (2018–2030)

Figure 72: The France Market Size of Anemia in USD Million (2018–2030)

Figure 73: The France Market Size of Anemia by Therapies (2018–2030)

Figure 74: The Italy Market Size of Anemia in USD Million (2018–2030)

Figure 75: The Italy Market Size of Anemia by Therapies (2018–2030)

Figure 76: The Spain Market Size of Anemia in USD Million (2018–2030)

Figure 77: The Spain Market Size of Anemia by Therapies (2018–2030)

Figure 78: The United Kingdom Market Size of Anemia in USD Million (2018–2030)

Figure 79: The United Kingdom Market Size of Anemia by Therapies (2018–2030)

Figure 80: Japan Market Size of Anemia in USD Million (2018–2030)

Figure 81: The Japan Market Size of Anemia by Therapies (2018–2030)

• AMAG Pharmaceuticals

• Vifor Pharma Inc.

• Rockwell Medical.

• Keryx Biopharmaceuticals Inc.

• Sanofi-Aventis U.S. LLC.

• Shield Therapeutics plc.

• Pharmacosmos A/S

• American Regent/Vifor

• Amgen Inc.

• Japan Tobacco

• FibroGen/AstraZeneca

• GlaxoSmithKline

• Akebia Therapeutics

• BioAge Labs Inc.

• Nemysis

• MegaPro Biomedical

• Bayer

  • Tags:
  • Anemia in Elderly market
  • Anemia in Elderly market research
  • Anemia in Elderly market insight
  • Anemia in Elderly market trends
  • Anemia in Elderly market forecast
  • Anemia in Elderly market share
  • Anemia in Elderly pipeline drugs
  • Anemia in Elderly treatment algori...
  • Anemia in Elderly drugs
  • Anemia in Elderly sales forecastin...
  • Anemia in Elderly market size
  • Anemia in Elderly disease
  • Anemia in Elderly epidemiology
  • Anemia in Elderly

Forward to Friend

Need A Quote